|
Oct 2
|
Orbimed Advisors LLC Reduces Stake in TELA Bio Inc
|
|
Jul 25
|
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
|
Jul 22
|
TELA Bio to Announce Second Quarter 2024 Financial Results
|
|
May 13
|
TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript
|
|
May 11
|
TELA Bio First Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)
|
|
May 10
|
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 10
|
TELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued Growth
|
|
May 9
|
TELA Bio Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
TELA Bio to Announce First Quarter 2024 Financial Results
|
|
Apr 15
|
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
|
|
Apr 10
|
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
|
|
Apr 8
|
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
|
|
Mar 24
|
Analysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Results
|
|
Mar 23
|
TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)
|
|
Mar 22
|
TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Q4 2023 TELA Bio Inc Earnings Call
|
|
Mar 21
|
TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023
|
|
Mar 21
|
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 21
|
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
|
|
Mar 21
|
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
|